Aakaar Medical Technologies Limited will hold its 13th Annual General Meeting on Tuesday, June 30, 2026, at 3:00 P.M. IST through video conference and other audio visual means. The meeting will be held to transact business as set out in the notice, complying with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. The company has completed the dispatch of the notice and the annual report for the financial year 2025-26 to shareholders whose email IDs were registered as of May 29, 2026. For members without registered email addresses, a physical letter containing the web-link to the reports was posted on June 5, 2026.

E-voting and Eligibility

The company has provided a remote e-voting facility through its Registrar and Share Transfer Agent, Bishare Services Pvt. Ltd. The remote e-voting period will commence on June 29, 2026, at 9:00 A.M. and conclude on the same day at 5:00 P.M. The cut-off date for determining eligibility for remote e-voting and voting during the AGM is June 23, 2026.

Members attending the AGM via video conference who have not cast their vote remotely may do so until 5:00 P.M. on June 30, 2026. Shareholders who have already voted remotely will not be entitled to vote again during the meeting.

Key AGM Dates

Shareholders with queries regarding e-voting may refer to the FAQs on the Bishare Services website or contact the company secretary at Aakaar Medical Technologies Limited.

Aakaar Medical Technologies Limited reported a 10% increase in Profit After Tax (PAT) to ₹6.63 crore for the financial year ended March 31, 2026, on revenue of ₹66.96 crore. The company maintained its profitability track record for the tenth consecutive year, with EBITDA for the period standing at ₹10.97 crore. The Board of Directors has recommended an Employee Stock Option Plan (ESOP) and an increase in authorised share capital, which will be placed before shareholders for approval at the upcoming Annual General Meeting (AGM).

Financial Performance

The company’s revenue from operations increased to ₹66.96 crore in FY26 from ₹61.58 crore in the previous year. Profit Before Tax (PBT) stood at ₹9.19 crore, compared to ₹8.11 crore in FY25. The EBITDA margin improved to 16.39% from 15.94% in the previous year. The cash and bank balance as of March 31, 2026, was recorded at ₹16.24 crore.

Strategic Resolutions

The Board has proposed several key resolutions for shareholder approval at the 13th AGM scheduled for June 30, 2026. A Special Resolution seeks approval for the 'Aakaar Medical Technologies Employees Stock Option Plan 2026'. The plan proposes granting up to 11,33,825 stock options, representing not more than 8% of the outstanding equity shares, to eligible employees and directors. The options will be exercisable into fully paid-up equity shares of ₹10 each.

Additionally, an Ordinary Resolution proposes increasing the authorised share capital from ₹15 crore to ₹15.40 crore by creating 4,00,000 additional equity shares of ₹10 each. This increase is intended to accommodate the issuance of ESOPs. The Board has also recommended the re-appointment of Shri Dilip Ramesh Meswani, Director retiring by rotation, and the appointment of M/s NAM & Associates as Secretarial Auditors for a term of five years commencing FY 2026-27.

Operational Highlights

During the year, the company expanded its customer base to over 6,300 doctors and clinics. The own-brand portfolio contributed 37% to the total revenue, supporting margin expansion. The company also launched several high-potential products, including Letybo, Saypha, and the VM Corp exosome suite, strengthening its position in the regenerative aesthetics segment. The IPO proceeds were utilized for working capital requirements, with ₹9.35 crore deployed till March 31, 2026.